胃癌雌激素受体表达及新一代抗受体药物在胃癌治疗中的探讨

目的　探讨胃癌雌激素受体 (ER)实际表达率 ,为临床使用新一代抗ER药物 (toremifene ,TOR)治疗胃癌提供临床病理依据。方法　用免疫组化法对 349例胃癌标本进行ER的检测 ,其中 2 99例用ABC(avidinbiotinperoxidasecomplex)法 ,5 0例用葡聚糖聚合物技术二步法进行检测。在检测ER的同时也检测 p5 3及PCNA的表达。结果　两种检测方法的ER阳性率分别为 2 .3% (7/ 2 99)及 0 % (0 / 5 0 ) ,p5 3阳性率 37.1% (111/ 2 99)及 4 6 %(2 3/ 5 0 ) ,PCNA 94 .3% (2 82 / 2 99)及 96 % (48/ 5 0 )。结论　胃癌细胞可表达ER但实际表达率很低 ,而且存在质和量的变化。tamoxifen (TAM )及TOR的抗胃癌效应需要进一步研究

Estrogen Receptor Expression in Gastric Cancer Cells and the Use of New Generation Anti-estrogenic Drug in the Treatment of Gastric Cancer

Purpose In this primary work we investigated on the exact expression of estrogenic receptor(ER) in gastric cancer,to provide a clinical basis for the use of new generation anti estrogenic drug toremifene (TOR) in the treatment of gastric cancer. Methods ER where detected immunohistochemically in 349 post gastrectomy gastric adenocarcinoma samples.avidin biotin peroxidase complex (ABC) method was used in 299 cases and the two steps method in 50 cases.Also expression of p53 and PCNA where investigated simultaneously. Results ER expression were 2.3% (7/299) and 0%(0/50) respectively.p53 expression were 37.1% (111/299) and 46%(23/50) respectively.PCNA expression were 94.3 %(282/299) and 96% (48/50) respectively. Conclusions Gastric cancer cells express estrogen receptors.However we think that the exact value of ER expression in this cancer is very low.We think that the anticancer effect of tamoxifen (TAM) and TOR on gastric adenocarcinoma needs more investigation.